Outcomes of high-risk adult outpatients with haematological malignancies treated with early remdesivir therapy during the SARS-CoV-2 omicron era: experiences from the national centre of Hungary

crossref(2022)

引用 0|浏览3
暂无评分
摘要
Abstract Objectives Emerging evidence suggests that remdesivir might improve clinical outcome of high-risk outpatients with COVID-19. Our aim was to evaluate characteristics and outcomes of non-hospitalized adults with haematological malignancies diagnosed with COVID-19 and treated with early remdesivir therapy during the omicron wave. Methods A single-centre prospective cohort study was performed among adult patients between February–June 2022, during the circulation of PANGO subvariants BA.2, BA.4 and BA.5 in Hungary. Patients were enrolled based on pre-defined criteria. Clinical characteristics (demography, comorbidities, vaccination status, imaging, treatment, and disease course) and outcomes (COVID-19 related hospitalisation, oxygen supplementation, intensive care support, all-cause death) were assessed at 28-days post-treatment. Results Altogether 127 patients were enrolled: 51.2% (65/127) were female with a median age of 59 ± 22 (21‒92) years, and 48.8% (62/127) had active haematological malignancy. At 28-days post-treatment, 7.1% (9/127) of patients required COVID-19 related hospitalisation, 2,4% (3/127) required oxygen supplementation, 1,6% (2/127) required intensive care, and 0.8% (1/127) died due to a non-COVID-19 related secondary infection at the intensive care unit, all with haematological malignancies. Conclusion Early remdesivir treatment might be a feasible strategy among high-risk outpatients with haematological malignancies and COVID-19 during the omicron wave.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要